📈 Jumpstart Signal Watchlist — July 28, 2026

🏢 What they do: Sotera Health is a global healthcare services company that provides sterilization solutions, laboratory testing, and technical advisory services to help ensure medical and pharmaceutical products are safe for use.
- 🎯 Current $17.76 is 8% below 3yr high $19.35 · ⏳ SMA200 $16.45 (current price $17.76 is above) · 💰 Market Cap $5.1B
- SHC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 280% (>20%); ROE 19% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.15 (<1.5).
⏰ Entry (E): 3/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Sotera Health (NASDAQ:SHC) Given Average Rating of "Moderate Buy" by Brokerages — MarketBeat.
🤖 This analyst roundup is mildly positive because it says 8 of 11 firms rate SHC a buy and assigns an average 1-year price target of $20.25, above the share price cited in the article. The piece also points to strong recent quarterly results, though it notes a large insider sale that partly offsets the tone.
✅ What Makes Sotera Health (SHC) a Strong Position in Your Portfolio? — Yahoo Finance.
🤖 This is broadly positive because it highlights SHC’s revenue growth, long-term strategy, and recent stock performance as reasons the company may be attractive. It is more of a bullish profile than a fresh catalyst, but it supports a constructive view of the stock.
⚪️ Sotera Health Company $SHC Shares Bought by Irenic Capital Management LP — MarketBeat.
🤖 The article is mostly a holdings update and repeats prior earnings and guidance, so it does not introduce a clear new operating catalyst. The inclusion of existing FY2026 guidance and consensus buy-side commentary is supportive, but the main news is ownership activity rather than a fundamental change.
🍭 Bonus (B): 0/10 — Misc Health & Allied Services

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $13.21 is 4% below 3yr high $13.71 · ⏳ SMA200 $8.68 (current price $13.21 is above) · 💰 Market Cap $889M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); ROE 15% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.16 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (14.6%)
- 🔔 Strong above EMA50 (23.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Bioventus (NASDAQ:BVS) Hits New 12-Month High — MarketBeat.
🤖 The article says Bioventus reached a new 52-week high and rose 4.9% on the day, which is a clear positive price signal. It also cites strong quarterly results with EPS of $0.15 versus $0.09 expected and notes a broadly bullish analyst consensus.
✅ Bioventus shares rise after Medicare reverses reimbursement cuts — Investing.com.
🤖 This is positive because the stock jumped after CMS reversed earlier reimbursement cuts for Bioventus’s non-invasive bone growth stimulators. That improves the reimbursement backdrop for an important product category and directly supports the stock.
⚪️ 315,018 Shares in Bioventus Inc. $BVS Bought by Engine Capital Management LP — MarketBeat.
🤖 This is mainly a holdings/filing update and does not provide operating or financial news, so its direct impact on the stock is limited. The article does not present new company fundamentals, guidance, or a material event beyond an investor stake change.
⚪️ Eversept Partners LP Lowers Stake in Bioventus Inc. $BVS — MarketBeat.
🤖 This filing-style item reports an investor reducing its position, but it does not describe a new operational development at Bioventus. The article largely repeats prior earnings information, so it is only mildly informative for the stock.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 At/above 3yr high $22.14 (current $22.14) · ⏳ SMA200 $14.32 (current price $22.14 is above) · 💰 Market Cap $607M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.50 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (10.2%)
- 🔔 Strong above EMA50 (16.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Ooma (NYSE:OOMA) Reaches New 1-Year High - Here's Why — MarketBeat.
🤖 The article says Ooma hit a new 52-week high, which reflects strong recent market momentum. It also cites prior earnings beats and multiple bullish analyst ratings and price targets, which are supportive for the stock.
✅ Hillsdale Investment Management Inc. Purchases New Position in Ooma, Inc. — MarketBeat.
🤖 The piece reports that Hillsdale Investment Management initiated a sizable new stake in Ooma, which can be read as a positive institutional signal. It also notes other funds increasing holdings, reinforcing the bullish ownership trend.
⚪️ Ooma SVP & chief legal officer Jenny Yeh sells shares — Investing.com.
🤖 This is a routine insider sale disclosure and does not by itself change Ooma’s operating outlook. It may be mildly negative in tone, but the article also notes the stock was trading near its 52-week high.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 At/above 3yr high $54.30 (current $54.30) · ⏳ SMA200 $37.84 (current price $54.30 is above) · 💰 Market Cap $2.8B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (8.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (9.1%)
- 🔔 Strong above EMA50 (15.6%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ John Wiley & Sons (NYSE:WLY) Sets New 52-Week High — MarketBeat.
🤖 The stock reached a new 52-week high, which is generally a bullish price signal. The article also ties the move to Wiley’s recently reported earnings beat on EPS and its dividend increase, both supportive for sentiment.
✅ The Bull Case For John Wiley & Sons (WLY) Could Change Following 33rd Straight Dividend Hike And Earnings Update — Yahoo Finance.
🤖 Wiley reported fourth-quarter sales of US$447.94 million and full-year net income of US$221.62 million, while the board approved a quarterly dividend of US$0.3575 per share. The dividend hike and profitability update are favorable for the stock, even though revenue was not a major beat.
🍭 Bonus (B): 0/10 — Book Publishing

🏢 What they do: Pediatrix Medical Group, Inc. (ticker: MD) is one of the nation's largest providers of physician-led prenatal, neonatal, maternal-fetal, and pediatric subspecialty services. The company partners with nearly 400 hospitals across 36 states, staffing NICUs and delivering coordinated, evidence-based care to women, babies, and children through a network of over 4,400 affiliated clinicians.
- 🎯 Current $26.86 is 2% below 3yr high $27.39 · ⏳ SMA200 $21.87 (current price $26.86 is above) · 💰 Market Cap $2.2B
- MD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 57/60
- 🏦 Low drawdown (14.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 50% (>20%); ROE 20% (>15%); Low LT D/E 0.70 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Pediatrix Medical Group Provides Second Quarter Update — Business Wire.
🤖 Pediatrix said second-quarter business trends were stable and reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million. Reaffirming guidance and stable payer mix are generally supportive for the stock.
✅ Pediatrix tegaskan kembali outlook 2026 di tengah tren payor yang stabil — Investing.com.
🤖 This article reports the same company update: stable second-quarter payer mix and a reaffirmed 2026 Adjusted EBITDA range of $280 million to $300 million. That combination typically signals management confidence and is modestly positive for $MD.
⚪️ Is Pediatrix Medical Group (MD) Overvalued As It Reaffirms ... — Yahoo Finance.
🤖 This is an analysis piece reacting to the company’s update and discussing valuation and recent share performance, but it does not report new operating news beyond the reaffirmed outlook. The valuation framing makes it broadly neutral for near-term stock movement.
🍭 Bonus (B): 0/10 — Hospitals

🏢 What they do: CSX Corporation is a holding company primarily operating CSX Transportation, a Class I freight railroad with over 21,000 miles of track in the eastern United States and parts of Canada. It transports commodities and manufactured goods, including merchandise freight (e.g., chemicals, metals, automotive), bulk freight, intermodal containers, and provides vehicle shipping services.
- 🎯 Current $50.84 is 4% below 3yr high $53.23 · ⏳ SMA200 $40.92 (current price $50.84 is above) · 💰 Market Cap $94.6B
- CSX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 Low drawdown (11.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 23% (>20%); ROE 38% (>15%); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ CSX Corp. Announces Second Quarter 2026 Results — Yahoo Finance / Globe Newswire.
🤖 CSX reported record quarterly revenue of $3.94 billion, with EPS up 23% year over year and operating margin expanding to 38.3%. The strong top- and bottom-line beat is favorable for the stock.
✅ CSX Q2 2026 slides: record revenue, margin expansion top estimates — Investing.com.
🤖 This coverage says CSX beat expectations on revenue and earnings, with shares rallying after the report. The article highlights record revenue, margin expansion, and strong operational leverage, all supportive for the stock.
✅ CSX Reports Q2 2026 Results: Full Earnings Call Transcript — Benzinga.
🤖 The transcript says CSX raised its full-year 2026 outlook after posting higher revenue, volume growth, and improved margins. A higher outlook and better operating performance are positive signals for investors.
🍭 Bonus (B): 0/10 — Railroads

🏢 What they do: Aramark is a global provider of outsourced food services, facilities management, and uniform services to clients in education, healthcare, business, sports, leisure, and corrections sectors .
- 🎯 Current $57.40 is 1% below 3yr high $58.15 · ⏳ SMA200 $43.77 (current price $57.40 is above) · 💰 Market Cap $15.1B
- ARMK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (7.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 65% (>20%); Low LT D/E 0.00 (<1.0); PEG ratio 0.66 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Entropy Technologies LP Makes New Investment in Aramark (ARMK) — MarketBeat.
🤖 The article highlights new institutional buying in ARMK and notes that multiple analysts remain constructive on the stock. It is also supported by Aramark’s prior earnings beat and raised FY2026 guidance, which are favorable signals for the shares.
✅ Aramark $ARMK Stock Position Increased by Sunriver Management LLC — MarketBeat.
🤖 This piece reports increased institutional ownership and reiterates strong prior-quarter results, including an earnings and revenue beat plus raised FY2026 guidance. It also references a generally positive analyst backdrop, which is supportive for the stock.
✅ Aramark (NYSE:ARMK) Sets New 1-Year High - Time to Buy? — MarketBeat.
🤖 The article says ARMK hit a new 52-week high, reflecting strong recent share performance. It also cites a moderate buy consensus, strong earnings, and upbeat guidance, all of which are positive for the stock.
🍭 Bonus (B): 0/10 — Restaurants